Table 2.
Diagnostic accuracy of plasma pTau181, NfL, Aβ42/40 ratio and CSF pTau181
Dx vs Dx | Test | n per group | AUC | 95% CI | p-value* | Sensitivity | Specificity | Cut point (pg/mL) |
---|---|---|---|---|---|---|---|---|
FTP-PET positive vs negative, only MCI | pTau181, plasma | 11 vs 20 | 0.977 | 0.929-1.000 | <0.0001 | 0.909 | 0.950 | 8.1 |
Autopsy confirmed: AD vs FTLD-TDP | pTau181, plasma | 15 vs 15 | 0.947 | 0.873-1.000 | <0.0001 | 1.000 | 0.800 | 9.4 |
Aβ-PET positive vs negative, only MCI | pTau181, plasma | 18 vs 21 | 0.944 | 0.873-1.000 | <0.0001 | 0.944 | 0.857 | 8.4 |
Clinical AD vs FTLD | pTau181, CSF | 16 vs 29 | 0.931 | 0.854-1.000 | <0.0001 | 0.875 | 0.897 | 67.0 |
FTP-PET positive vs negative (all) | pTau181, plasma | 60 vs 37 | 0.919 | 0.863-0.976 | <0.0001 | 0.917 | 0,838 | 8.1 |
Aβ-PET positive vs negative (all) | pTau181, plasma | 90 vs 95 | 0.914 | 0.869-0.958 | <0.0001 | 0.889 | 0.853 | 8.0 |
Clinical AD vs FTLD | pTau181, plasma | 56 vs 190 | 0.894 | 0.855-0.933 | <0.0001 | 0.982 | 0.711 | 8.7 |
Autopsy confirmed: AD vs combined FTLD-TDP + FTLD-tau | pTau181, plasma | 15 vs 67 | 0.878 | 0.798-0.957 | <0.0001 | 1.000 | 0.672 | 9.5 |
Aβ-PET positive vs negative, healthy controls only | pTau181, plasma | 11 vs 29 | 0.859 | 0.732-0.986 | 0.001 | 0.818 | 0.828 | 7.6 |
Autopsy confirmed: AD vs FTLD-tau | pTau181, plasma | 15 vs 52 | 0.858 | 0.765-0.950 | <0.0001 | 1.000 | 0.635 | 9.6 |
Autopsy confirmed: AD vs FTLD + mutation carriers | pTau181, plasma | 15 vs 115 | 0.854 | 0.772-0.937 | <0.0001 | 1.000 | 0.626 | 8.9 |
FTP-PET positive vs negative | Aβ42/40 ratio, plasma | 42 vs 34 | 0.782 | 0.674-0.890 | <0.0001 | 0.647 | 0.857 | 0.16 |
Aβ-PET positive vs negative | Aβ42/40 ratio, plasma | 68 vs 67 | 0.768 | 0.686-0.849 | <0.0001 | 0.567 | 0.926 | 0.15 |
Autopsy confirmed: AD vs FTLD-TDP | Plasma NfL | 7 vs 14 | 0.765 | 0.557-0.973 | 0.052 | 0.643 | 1.000 | 53.7 |
Autopsy confirmed: FTLD-TDP vs FTLD-tau | pTau181, plasma | 15 vs 52 | 0.664 | 0.499-0.829 | 0.054 | 0.981 | 0.333 | 9.6 |
Autopsy confirmed: AD vs combined FTLD-TDP + FTLD-tau | NfL, plasma | 6 vs 63 | 0.656 | 0.369-0.774 | 0.209 | 0.429 | 1.000 | 48.7 |
Autopsy confirmed: FTLD-TDP vs FTLD-tau | NfL, plasma | 13 vs 50 | 0.655 | 0.494-0.817 | 0.086 | 0.615 | 0.700 | 55.0 |
Autopsy confirmed: AD vs FTLD + mutation carriers | NfL, plasma | 6 vs 70 | 0.633 | 0.439-0.828 | 0.281 | 0.414 | 1.000 | 48.0 |
FTP-PET positive vs negative | NfL, plasma | 34 vs 27 | 0.606 | 0.446-0.765 | 0.159 | 0.824 | 0.556 | 64.5 |
Aβ-PET positive vs negative | NfL, plasma | 51 vs 67 | 0.559 | 0.453-0.664 | 0.276 | 0.433 | 0.882 | 42.7 |
Cut-off value is adjusted for age, autopsy confirmed cut-off is adjusted for age and CDRsb.
Abbreviations: Aβ, beta-amyloid; AD, Alzheimer’s disease; AUC, Area under the curve; CSF, Cerebrospinal fluid; FTP-PET, 18F-Flortaucipir PET; MCI, mild cognitive impairment; NfL, neurofilament light chain; PET, positron emission tomography; pTau181, phosphorylated tau 181
p-value corrected for False Discovery Rate